AstraZeneca discontinues prostate cancer treatment trial

(Sharecast News) - AstraZeneca has discontinued its CAPItello-280 phase three trial assessing Truqap, or capivasertib, in combination with docetaxel and androgen-deprivation therapy (ADT) for patients with metastatic castration-resistant prostate cancer (mCRPC). The FTSE 100 drugmaker said the decision followed a recommendation from the Independent Data Monitoring Committee after a pre-specified interim analysis concluded that the combination was unlikely to meet the trial's dual primary endpoints of radiographic progression-free survival and overall survival.

It said the safety profile of Truqap remained consistent with previous studies.

The CAPItello-280 trial had enrolled 1,033 adult patients globally, aiming to address the high unmet need in mCRPC, a condition associated with poor survival rates and limited effective treatment options.

AstraZeneca said it would work with investigators to ensure patient follow-up and that the data generated will inform ongoing research efforts.

Truqap, a first-in-class AKT inhibitor discovered by AstraZeneca, is already approved in several major markets for HR-positive, HER2-negative breast cancer in combination with Faslodex.

It remains under investigation in other ongoing phase three trials targeting both breast and prostate cancers.

Reporting by Josh White for Sharecast.com.